PT KALBE FARMA TBK. Press Release No. 049/KFCP-DIR/PR/IX/21
Jakarta, September 18, 2021, PT Kalbe Farma Tbk (Kalbe)today announced the 3 best recipients of the Research and Technology/BRIN Kalbe Science Award (RKSA) 2021 which have been rigorously selected from 9 potential recipients of funding with research titles accepted from all over Indonesia by the Council The judges for the 2021 RKSA are 282 titles. Furthermore, the three recipients of the RKSA funds will develop their research in order to realize the RKSA 2021 mission, namely Downstreaming Research to Health the Nation. RKSA 2021 is a program to provide research funding for researchers in Indonesia with the themes of Farma and Biopharma, Cell and genetherapy, e-health, medical devices, diagnostics, health food and drink and natural product products. The results of the research are expected to be able to achieve the downstream process to become a product or service that can be enjoyed by the community. The announcement of the 3 recipients of RKSA research funds was carried out together with a scientific discussion themed 'Digital Optimization to Support Research Downstream' with Prof. Widodo, S.Si.,M.Si.,Ph.D.Med.Sc - Dean of the Faculty of Mathematics and Natural Sciences Universitas Brawijaya and Dr. dr. Bayu Prawira Hie, MBA - Chairman of the Supervisory Board of the Indonesian Telemedicine Alliance (ATENSI).
The selection of proposals made by the Jury refers to predetermined criteria, namely product and market readiness in terms of advantages over similar or equally useful products for users; a combination of Technology Readiness Level (TRL) and Demand Readiness Level (DRL); the suitability of the research methodology with the research objectives; the suitability of the budget (RAB) with the research objectives and the suitability between the timeline and the research objectives.
The three recipients of the 2021 RKSA funds are:
1. David S. Perdanakusuma with the research title The Effectiveness of Mesenchymal Stem Cell-Secretome (UCMSC-S) Gel Against Wound Reepithelialization Acceleration.
2. Bintang Soetjahjo with the research title Effectiveness of Provision of Media Therapy Conditioned Allogenic Cord Mesenchymal Stem Cells in Osteoarthritis Patients of the Knee Joint.
3. Alex Lukmanto Suherman with the research title Development of a Rapid Test Kit Based on Single-Entity Electrochemistry (SEE) for the Detection of Covid-19 in Saliva.
'We appreciate Kalbe for conducting RKSA since 2008 and hope that through this RKSA program it can support research products that are ready to be downstream. Thus, RKSA can trigger researchers to be more active in translating research results into products or services that can be used by the community to make the nation healthy,' said Dr. Laksana Tri Handoko, M.Sc., Head of the National Research and Innovation Agency (BRI). 'BRIN as a facilitator of researchers in Indonesia is committed to continuing to support the RKSA program so that it becomes a role model for researchers to innovate and research research products that can be utilized by the community to nourish the nation,' added Dr. Handoko.
'RKSA 2021 is the result of collaboration between the Ministry of Research and Technology / BRIN and Kalbe in strengthening the triple helix collaboration between Academics, Business and Government and other research communities to increase the downstreaming of research in the health sector,' said Vidjongtius, President Director of PT Kalbe Farma Tbk. 'Since 2018, RKSA has focused on providing research funds for selected researchers to lead to the downstream process so that the results can be enjoyed by the community,' Vidjongtius continued.
Vidjongtius added that the pre-proposals received this year were 282 research titles, which were then selected into 30 proposals to become 9 finalists who presented them in front of the jury. The research categories are Pharma and Biopharma, Cell and genetherapy, e-health, medical devices, diagnostics, health food and drink and natural products. 'Kalbe continues to be committed to the world of research, especially in the health sector and hopes that this downstream process can produce products that can be used by the community to nourish the nation,' continued Vidjongtius.
The process of organizing the 2021 RKSA goes through several stages, namely the stage of receiving pre-proposal Jan - April, pre-proposal May - June. The next stage is receiving proposals in July, evaluating proposals for receiving August and research proposals that will be funded in September 2021. Then for a year the research goes through a monitoring and evaluation process by the 2021 RKSA jury and 3 recipients of research funds are announced.
In the RKSA webinar, it was also conveyed that digital optimization to support downstream research, especially in the face of the COVID-19 pandemic, was delivered by Prof. Widodo, S.Si., M.Sc., Ph.D.Med.Sc, Dean of the Faculty of Mathematics and Natural Sciences, Universitas Brawijaya and Dr. .dr. Bayu Prawira Hie, MBA, Chairman of the Supervisory Board of the Indonesian Telemedicine Alliance (ATENSI).
Conveying that seeing genetic variation can be done by preparing a functional appropriate to the genetic character.
Prof. Widodo, S.Si.,M.Si.,Ph.D.Med.Sc conveyed that digital technology plays an important role in research in the health sector, such as the example of making vaccines which initially had to go through many research processes, from checking the type of virus, multiplying the virus, screening, efficacy, clinical trial stage and general use. Meanwhile, with digital technology, we can accelerate research time with AI Bioinformatic and BIGData.
While Dr. dr. Bayu Prawira Hie, MBA also added that in the current COVID-19 pandemic situation, communication and information platforms, especially those related to health services, are required to be digital-based so that telemedicine services which include consulting services with doctors, delivering drugs, making doctor's appointments are carried out to reduce the risk of COVID-19 transmission. -19 and realizing adequate health services for all Indonesian people.
The RKSA 2021 jury consists of Prof. Dr. Amin Soebandrio, Ph.D, Sp.MK (Director of the Eijkman Institute for Molecular Biology), Dr. Ir. Bambang Setiadi, IPU (Chairman of the National Research Council), Dr. Ir. Roy Alexander Sparringa, M.App.SC. (BPPT Senior Advisor), Dr. Lucia Rizka Andalusia, Apt,. M. Pharm, MARS, (Director of Drug Registration of the Food and Drug Supervisory Agency), dr. Sandy Qlintang (Director of Stem Cell and Cancer Institute & Pharma Metric Labs of PT Kalbe Farma Tbk) and also an honorary jury from the Ministry of Research and Technology/BRIN and Founder of PT Kalbe Farma Tbk Dr. Boenjamin Setiawan, Ph.D.
Information about the 2021 RKSA program can be found at www.kalbe-rksa.com.
Kalbe at a glance
PT Kalbe Farma Tbk ('Kalbe') was established in 1966 and is one of the largest publicly listed pharmaceutical companies in Southeast Asia. Kalbe has four main divisions that handle a reliable and diverse brand portfolio; prescription medicine division (Cefspan, Brainact, Broadced, etc.); health products division that handles over-the-counter drugs (Promag, Mixagrip, Komix, Woods, Fatigon, etc.), multivitamins (Fatigon, H2, XonCe, Hevit-C, JossC1000 etc.), and supplement and ready-to-drink drinks (Hydro Coco, Extra Joss) , nutrition division (ChilKid, Prenagen, Diabetasol, Zee, etc.); and distribution division. Kalbe now has more than 40 subsidiaries and 14 production facilities with international standards, and employs approximately 17,000 employees, spread across 76 branches throughout Indonesia. Since 1991, Kalbe's shares have been listed on the Indonesia Stock Exchange (IDX:KLBF).
Attachments
- Original document
- Permalink
Disclaimer
PT Kalbe Farma Tbk published this content on 18 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 September 2021 03:31:04 UTC.
